Pembrolizumab Plus Axitinib and the Future of Further-line mRCC Treatments

By Nazli Dizman, MD - Last Updated: May 18, 2023

Nazli Dizman, MD, an Internal Medicine Resident at Yale University, discusses the combination of pembrolizumab and axitinib as a second- and further-line treatment of metastatic renal cell carcinoma.
Dr. Dizman describes other second- and further-line treatments that are commonly administered to patients with mRCC, as well as how the design of future trials testing novel immunotherapy combinations for treating mRCC may be influenced by her recent study.

View Dr. Dizman’s comments on the factors that may contribute to positive outcomes for patients receiving pembrolizumab/axitinib.